• 1
    Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol 2002; 187: 11626
  • 2
    Milsom I, Altman D, Herbison P et al. Epidemiology of urinary (UI) and faecal (FI) incontinence and pelvic organ prolapse (POP). In Abrams P, Cardozo L, Kouhry S, Wein A eds. Incontinence, Paris: Health Publications, 2009: 37111
  • 3
    Ko Y, Lin SJ, Salmon JW, Bron MS. The impact of urinary incontinence on quality of life of the elderly. Am J Manag Care 2005; 11: S10311
  • 4
    Kobelt G. Economic considerations and outcome measurement in urge incontinence. Urology 1997; 50: 10010
  • 5
    Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006; (4): CD003781
  • 6
    Homma Y, Kawabe K. Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World J Urol 2004; 22: 2516
  • 7
    Kelleher CJ, Cardozo L, Chapple CR, Haab F, Ridder AM. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int 2005; 95: 815
  • 8
    Kelleher CJ, Reese PR, Pleil AM, Okano GJ. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 2002; 8: S60815
  • 9
    Kelleher CJ, Tubaro A, Wang JT, Kopp Z. Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU Int 2008; 102: 5661
  • 10
    Khullar V, Hill S, Laval KU, Schiotz HA, Jonas U, Versi E. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology 2004; 64: 26975
  • 11
    Yamaguchi O, Marui E, Kakizaki H et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int 2007; 100: 57987
  • 12
    Wettermark BH, Fored N, Leimanis CM et al. The new Swedish Prescribed Drug Register – opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007; 16: 72635
  • 13
    Getsios D, Caro JJ, Ishak KJ et al. Oxybutynin extended release and tolterodine immediate release: a health economic comparison. Clin Drug Investig 2004; 24: 818
  • 14
    Hakkaart L, Verboom P, Phillips R, Al MJ. The cost utility of solifenacin in the treatment of overactive bladder. Int Urol Nephrol 2009; 41: 2938
  • 15
    Kobelt G, Jonsson L, Mattiasson A. Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model. Neurourol Urodyn 1998; 17: 599611
  • 16
    Milsom I, Axelsen S, Kulseng-Hansen S, Mattiasson A, Nilsson CG, Wickstrom J. Cost-effectiveness analysis of solifenacin flexible dosing in patients with overactive bladder symptoms in four Nordic countries. Acta Obstet Gynecol Scand 2009; 88: 6939
  • 17
    O'Brien BJ, Goeree R, Bernard L, Rosner A, Williamson T. Cost-effectiveness of tolterodine for patients with urge incontinence who discontinue initial therapy with oxybutynin: a Canadian perspective. Clin Ther 2001; 23: 203849
  • 18
    Speakman M, Khullar V, Mundy A, Odeyemi I, Bolodeoku J. A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome. Curr Med Res Opin 2008; 24: 21739
  • 19
    Cardozo L, Thorpe A, Warner J, Sidhu M. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. BJU Int 2010; 106: 50614
  • 20
    Malone-Lee J, Shaffu B, Anand C, Powell C. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. J Urol 2001; 165: 14526
  • 21
    SBU. Behandling av urininkontinens. SBU-Rapport Nr 143: Statens Beredning För Medicinsk Utvärdering. Stockholm: SBU, 2000
  • 22
    Linnér LS, Schiöler H, Samuelsson E, Milsom I, Nilsson F. Low persistence of anticholinergic drug use in Sweden. Eur J Clin Pharmacol 2010; 67: 5356
  • 23
    SWEDIS. Swedish Drug Information System . 2010
  • 24
    Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006; 29: 38596
  • 25
    Meek PD, Evang SD, Tadrous M, Roux-Lirange D, Triller DM, Gumustop B. Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials. Dig Dis Sci 2011; 56: 718
  • 26
    Milsom I. Lower urinary tract symptoms in women. Curr Opin Urol 2009; 19: 33741
  • 27
    Samuelsson E, Mansson L, Milsom I. Incontinence aids in Sweden: users and costs. BJU Int 2001; 88: 8938
  • 28
    Chapple CR, Martinez-Garcia R, Selvaggi L et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005; 48: 46470
  • 29
    Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001; 57: 41421
  • 30
    Brazier J, Czoski-Murray C, Roberts J, Brown M, Symonds T, Kelleher C. Estimation of a preference-based index from a condition-specific measure: the King's Health Questionnaire. Med Decis Making 2008; 28: 11326
  • 31
    Ko Y, Malone DC, Armstrong EP. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder. Pharmacotherapy 2006; 26: 1694702
  • 32
    Johannesson M, O'Conor RM, Kobelt-Nguyen G, Mattiasson A. Willingness to pay for reduced incontinence symptoms. Br J Urol 1997; 80: 55762
  • 33
    Nygaard I. Clinical practice. Idiopathic urgency urinary incontinence. N Engl J Med 2010; 363: 115662
  • 34
    National Institute for Health and Clinical Excellence. Urinary Incontinence – the Management of Urinary Incontinence in Women. London: NICE, 2006
  • 35
    Kraus SR, Bavendam T, Brake T, Griebling TL. Vulnerable elderly patients and overactive bladder syndrome. Drugs Aging 2010; 27: 697713
  • 36
    Uusvaara J, Pitkala KH, Kautiainen H, Tilvis RS, Strandberg TE. Association of anticholinergic drugs with hospitalization and mortality among older cardiovascular patients: a prospective study. Drugs Aging 2011; 28: 1318
  • 37
    Kraus SR, Ruiz-Cerda JL, Martire D, Wang JT, Wagg AS. Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder. Urology 2010; 76: 13507
  • 38
    Griebling TL, Kraus SR, Richter HE, Glasser DB, Carlsson M. Tolterodine extended release is well tolerated in older subjects. Int J Clin Pract 2009; 63: 1198204
  • 39
    Macdiarmid SA. Concomitant medications and possible side effects of antimuscarinic agents. Rev Urol 2008; 10: 928